Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

On May 15, 2020 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, reported it will present new preclinical data on three XmAb 2+1 bispecific antibody programs and an IL-12-Fc cytokine program at the second session of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting, being held June 22-24, 2020 (Press release, Xencor, MAY 15, 2020, View Source [SID1234558158]). Abstracts for these poster presentations are now available on AACR (Free AACR Whitepaper)’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Xencor has expanded our T-cell redirecting CD3 class of bispecific antibodies with a mixed valency format that uses the same heterodimeric Fc domain as our other bispecific antibodies and cytokines, but with two identical tumor targeting domains and one CD3 targeting domain—the XmAb 2+1 bispecific antibody. These two tumor-targeting binding domains can bind together when there’s more target present, a property called avidity," said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor. "Our 2+1 format, along with avidity tuning, enables higher selectivity for tumor antigen-expressing cells and greater flexibility in tuning the potency and potentially the efficacy and tolerability of the molecule, as well as the ability to address an expanded set of tumor antigens."

"At AACR (Free AACR Whitepaper), we are presenting data from preclinical models showing strong, selective tumor killing from XmAb 2+1 bispecific antibody programs that target PSMA, mesothelin and ENPP3, the last of which is an underexplored tumor antigen overexpressed on renal cell carcinomas. In addition, we are introducing our next cytokine program in oncology, a potency-reduced IL-12 Fc fusion, which demonstrates strong-anti-tumor activity in preclinical models, as a single agent and in combination with an anti-PD1 antibody," said Dr. Desjarlais.

Poster Presentation Details

Abstract: 2286
Title: XmAb30819, an XmAb 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in-vivo preclinical studies
Session: Therapeutic Antibodies 1
Abstract: 5663
Title: Affinity tuned XmAb 2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models
Session: Therapeutic Antibodies 4
Abstract: 5654
Title: Affinity tuned XmAb 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell directed cell cytotoxicity of human ovarian cancer cells
Session: Therapeutic Antibodies 4
Abstract: 5549
Title: Potency-reduced IL-12 heterodimeric Fc-fusions exhibit strong anti-tumor activity
Session: Immunomodulatory Agents and Interventions 2
These posters and audio descriptions will be available to registrants of the AACR (Free AACR Whitepaper) Virtual Annual Meeting at 9:00 a.m. EDT on Monday, June 22. Posters will be archived under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com.